Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaunoDouble: Daunorubicin Dose and Induction Cycles in AML
NCT02140242Phase 3Completed
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2014
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of daunorubicin in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Started Apr 2014; status: completed.
02
Drugs
daunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02140242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140242.